ImmunoPrecise Antibodies Ltd (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, said on Thursday that its subsidiary Talem has entered into a research collaboration and exclusive option licence agreement with Xyphos Biosciences Inc, a subsidiary of Japanese pharmaceutical company Astellas Pharma Inc (Tokyo:4503).
Under this agreement the two companies will jointly conduct research activities to identify and optimise proprietary LENSai in silico generated antibodies, targeting an undisclosed target in the tumour microenvironment (TME), as potential therapeutic development candidates.
Targeting this molecule in the TME has the potential to markedly enhance anti-tumour immunity with other Astellas therapies including chimeric antigen receptor-based (CAR) technologies, ImmunoPrecise said.
Astellas will have the exclusive option to license any development candidates generated as part of the collaboration.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval